MA45890A1 - Composition pharmaceutique destinée à prévenir une dépendance aux opioïdes - Google Patents
Composition pharmaceutique destinée à prévenir une dépendance aux opioïdesInfo
- Publication number
- MA45890A1 MA45890A1 MA45890A MA45890A MA45890A1 MA 45890 A1 MA45890 A1 MA 45890A1 MA 45890 A MA45890 A MA 45890A MA 45890 A MA45890 A MA 45890A MA 45890 A1 MA45890 A1 MA 45890A1
- Authority
- MA
- Morocco
- Prior art keywords
- patient
- pharmaceutical composition
- opioids
- composition intended
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Addiction (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
L'invention concerne une composition pharmaceutique destinée à prévenir une dépendance aux opioïdes chez un patient. La composition peut être utilisée chez un patient souffrant de lombalgie (lbp) modérée à sévère. La composition est avantageuse chez un patient ayant reçu un diagnostic de lombalgie, et comprend une quantité thérapeutiquement efficace d'un anticorps qui se lie plus particulièrement au facteur de croissance nerveuse (ngf) ou d'un fragment de liaison à l'antigène de ce dernier; et elle est utilisée en l'absence d'un opioïde servant à atténuer la douleur, et prévient la dépendance aux opioïdes chez un patient.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662427365P | 2016-11-29 | 2016-11-29 | |
| PCT/US2017/063417 WO2018102294A1 (fr) | 2016-11-29 | 2017-11-28 | Composition pharmaceutique destinée à prévenir une dépendance aux opioïdes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA45890A1 true MA45890A1 (fr) | 2020-02-28 |
| MA45890B2 MA45890B2 (fr) | 2022-10-31 |
Family
ID=60766150
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046951A MA46951A (fr) | 2016-11-29 | 2017-11-28 | Composition pharmaceutique destinée à prévenir une dépendance aux opioïdes |
| MA45890A MA45890B2 (fr) | 2016-11-29 | 2017-11-28 | Composition pharmaceutique destinée à prévenir une dépendance aux opioïdes |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046951A MA46951A (fr) | 2016-11-29 | 2017-11-28 | Composition pharmaceutique destinée à prévenir une dépendance aux opioïdes |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10736961B2 (fr) |
| EP (1) | EP3548082B1 (fr) |
| JP (1) | JP7071975B2 (fr) |
| KR (1) | KR20190090820A (fr) |
| CN (1) | CN110072549A (fr) |
| AU (1) | AU2017366870B2 (fr) |
| BR (1) | BR112019010331A2 (fr) |
| CA (1) | CA3045116A1 (fr) |
| CL (1) | CL2019001385A1 (fr) |
| CO (1) | CO2019005247A2 (fr) |
| EA (1) | EA201991283A9 (fr) |
| IL (1) | IL266640B (fr) |
| MA (2) | MA46951A (fr) |
| MX (1) | MX2019006013A (fr) |
| MY (1) | MY200701A (fr) |
| PH (1) | PH12019501087A1 (fr) |
| WO (1) | WO2018102294A1 (fr) |
| ZA (1) | ZA201902967B (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210043624A (ko) * | 2018-08-10 | 2021-04-21 | 리제너론 파아마슈티컬스, 인크. | 무릎 및/또는 고관절 통증의 안전하고 효과적인 치료를 위한 약제학적 조성물 |
| EP4433500A1 (fr) | 2021-11-19 | 2024-09-25 | Regeneron Pharmaceuticals, Inc. | Méthodes et compositions pour réduire la douleur centralisée |
| WO2023212586A1 (fr) | 2022-04-27 | 2023-11-02 | Regeneron Pharmaceuticals, Inc. | Procédés de sélection de patients pour le traitement avec un antagoniste du ngf |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| DK2270048T3 (en) | 2002-12-24 | 2016-01-18 | Rinat Neuroscience Corp | Anti-NGF antibodies and methods for their use |
| US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
| ME00226B (me) | 2004-07-15 | 2011-02-10 | Medarex Llc | Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade |
| JP5307708B2 (ja) | 2006-06-02 | 2013-10-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトｉｌ−６受容体に対する高親和性抗体 |
| MX2010001395A (es) | 2007-08-10 | 2010-03-10 | Regeneron Pharma | Anticuerpos humanos de alta afinidad de factor de crecimiento de nervio humano. |
| NZ609557A (en) | 2010-10-06 | 2014-12-24 | Regeneron Pharma | Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies |
-
2017
- 2017-11-28 IL IL266640A patent/IL266640B/en unknown
- 2017-11-28 CN CN201780073865.2A patent/CN110072549A/zh active Pending
- 2017-11-28 US US15/824,106 patent/US10736961B2/en active Active
- 2017-11-28 MX MX2019006013A patent/MX2019006013A/es unknown
- 2017-11-28 EP EP17817965.1A patent/EP3548082B1/fr active Active
- 2017-11-28 BR BR112019010331-7A patent/BR112019010331A2/pt unknown
- 2017-11-28 KR KR1020197018394A patent/KR20190090820A/ko not_active Ceased
- 2017-11-28 AU AU2017366870A patent/AU2017366870B2/en active Active
- 2017-11-28 EA EA201991283A patent/EA201991283A9/ru unknown
- 2017-11-28 JP JP2019525911A patent/JP7071975B2/ja active Active
- 2017-11-28 MA MA046951A patent/MA46951A/fr unknown
- 2017-11-28 CA CA3045116A patent/CA3045116A1/fr active Pending
- 2017-11-28 WO PCT/US2017/063417 patent/WO2018102294A1/fr not_active Ceased
- 2017-11-28 MY MYPI2019002915A patent/MY200701A/en unknown
- 2017-11-28 MA MA45890A patent/MA45890B2/fr unknown
-
2019
- 2019-05-13 ZA ZA2019/02967A patent/ZA201902967B/en unknown
- 2019-05-16 PH PH12019501087A patent/PH12019501087A1/en unknown
- 2019-05-22 CL CL2019001385A patent/CL2019001385A1/es unknown
- 2019-05-22 CO CONC2019/0005247A patent/CO2019005247A2/es unknown
-
2020
- 2020-07-02 US US16/920,178 patent/US11491222B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN110072549A (zh) | 2019-07-30 |
| CO2019005247A2 (es) | 2019-05-31 |
| JP2019535716A (ja) | 2019-12-12 |
| MX2019006013A (es) | 2019-10-14 |
| PH12019501087A1 (en) | 2019-08-19 |
| US10736961B2 (en) | 2020-08-11 |
| US11491222B2 (en) | 2022-11-08 |
| US20180147280A1 (en) | 2018-05-31 |
| EA201991283A1 (ru) | 2019-09-30 |
| ZA201902967B (en) | 2024-10-30 |
| JP7071975B2 (ja) | 2022-05-19 |
| IL266640B (en) | 2022-09-01 |
| EA201991283A9 (ru) | 2019-11-27 |
| EP3548082A1 (fr) | 2019-10-09 |
| MA45890B2 (fr) | 2022-10-31 |
| WO2018102294A1 (fr) | 2018-06-07 |
| CL2019001385A1 (es) | 2019-07-26 |
| MA46951A (fr) | 2019-10-09 |
| KR20190090820A (ko) | 2019-08-02 |
| BR112019010331A2 (pt) | 2019-10-22 |
| CA3045116A1 (fr) | 2018-06-07 |
| AU2017366870B2 (en) | 2024-09-19 |
| IL266640A (en) | 2019-07-31 |
| US20210060159A1 (en) | 2021-03-04 |
| EP3548082B1 (fr) | 2024-05-15 |
| MY200701A (en) | 2024-01-11 |
| AU2017366870A1 (en) | 2019-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101155294B1 (ko) | 면역특이적으로 ＢＬｙＳ에 결합하는 항체 | |
| MA56289B1 (fr) | Mutéines d'interleukine-21 et méthodes de traitement | |
| MA40476A (fr) | Anticorps et fragments de fixation à l'antigène anti-lag3 | |
| MA30353B1 (fr) | Anticorps se liant à la protéine tyrosine phosphatase bêta humaine (hptpbêta) et utilisations correspondantes. | |
| MA35345B1 (fr) | Proteines de liaisons a un antigene ayant une liaison accrue a fcrn | |
| MA37761A1 (fr) | Protéines de liaison à un antigène antagoniste d'un double récepteur et leurs utilisations | |
| MA33724B1 (fr) | Anticorps neutralisants anti-ngf humain en tant qu'inhibiteurs selectifs de la voie du ngf | |
| EA201170157A1 (ru) | Notch-связывающие агенты и антагонисты и способы их применения | |
| MA46665B1 (fr) | Composés de tyrosine tyrosine de peptide cyclique couplés à un anticorps en tant que modulateurs des récepteurs du neuropeptide y | |
| CR20210492A (es) | ANTICUERPOS CONTRA AMILOIDES-ß CON PIROGLUTAMATO Y USOS DE ESTOS | |
| BRPI0410129B8 (pt) | anticorpo anti-cs1 isolado, fragmento de ligação de antígeno, composto conjugado e composição farmacêutica | |
| MA33387B1 (fr) | Polypeptides et procede de traitement | |
| AR083819A1 (es) | UN ANTICUERPO QUE SE UNE A BACE1 (ENZIMA 1 DE DISOCIACION DE PROTEINA PRECURSORA DEL AMILOIDE DE SITIO b), METODOS Y COMPOSICIONES PARA INMUNOTERAPIA PARA ENFERMEDAD NEURAL | |
| MA45890A1 (fr) | Composition pharmaceutique destinée à prévenir une dépendance aux opioïdes | |
| EA202190335A1 (ru) | Композиции антител против fcrn и способы их применения | |
| BR112014014824A2 (pt) | anticorpos antagonistas do receptor do hormônio de crescimento humano e métodos de uso dos mesmos | |
| MA61946B1 (fr) | Anticorps capables de se lier à la protéine spike du coronavirus sars-cov-2 | |
| MX2024005430A (es) | Composiciones, formas farmaceuticas y metodos de anticuerpos anti-tau. | |
| MX2024008933A (es) | Anticuerpos anti-musk para uso en el tratamiento de trastornos neuromusculares. | |
| EP3682898A4 (fr) | Composition pharmaceutique comprenant un anticorps se liant de manière spécifique à l'extrémité n-terminale de la lysyl-arnt synthétase en tant que principe actif pour la prévention ou le traitement d'une maladie liée à la migration des cellules immunitaires | |
| AR111767A1 (es) | Proteínas de unión al antígeno anti-jagged1 | |
| MA41668A1 (fr) | Composition multi-pertidique | |
| AU2020271352A8 (en) | Combinations of anti-ILDR2 antibodies and PD-1 antagonists | |
| BR112022001522A2 (pt) | Anticorpo igg1 modificado ou fragmento de ligação ao antígeno deste, método de aumento da capacidade de morte celular direta de um anticorpo igg1 ou fragmento de ligação ao antígeno deste, composição farmacêutica, método de tratamento de um indivíduo que apresenta uma doença, método de tratamento de um indivíduo, kit compreendendo um anticorpo igg1 modificado ou fragmento de ligação ao antígeno deste e uso de um anticorpo igg1 modificado ou fragmento de ligação ao antígeno deste | |
| MA48870B1 (fr) | Anticorps anti-sortiline et leurs méthodes d'utilisation |